Danaparoid
From Wikipedia, the free encyclopedia
|
Danaparoid
|
|
| Systematic (IUPAC) name | |
| ? | |
| Identifiers | |
| CAS number | ? |
| ATC code | B01 |
| PubChem | ? |
| Chemical data | |
| Formula | ? |
| Mol. mass | ? |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Danaparoid sodium (Orgaran) is an anticoagulant that works by inhibiting activated factor X (factor Xa).
Danaparoid is considered a "low molecular weight heparin" by some sources, but is chemically distinct from heparin and thus has little cross-reactivity in heparin-intolerant patients.
Contents |
[edit] Uses
It is used to prevent deep venous clots, particularly in situations with a high risk of clot formation, such as after hip surgery.
It is also used as a heparinoid substitute in heparin-induced thrombocytopenia which may otherwise cause paradoxical thrombosis.
[edit] Discontinuation
On August 14, 2002, this drug was withdrawn by Organon International.[1]
[edit] Administration
IV IV and SC
[edit] Side effects
- Bleeding problems
- Low platelets, due to a low level of structural similarity between danaparoid and heparin
- Asthma exacerbations, due to allergies to sulfites contained within the medicine
[edit] References
- ^ Danaparoid (Subcutaneous Route) - MayoClinic.com. Retrieved on 2007-08-23.
[edit] External links
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
